Clinical outcome measures for progressive MS trials

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis

(2017) Peter Feys et al.   Multiple Sclerosis Journal

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

(2017) Robert W Motl et al.   Multiple Sclerosis Journal

Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis

(2017) Laura J Balcer et al.   Multiple Sclerosis Journal

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis

(2017) Ralph HB Benedict et al.   Multiple Sclerosis Journal

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis

(2017) Peter Feys et al.   Multiple Sclerosis Journal

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

(2017) Robert W Motl et al.   Multiple Sclerosis Journal

Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis

(2017) Laura J Balcer et al.   Multiple Sclerosis Journal

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis

(2017) Ralph HB Benedict et al.   Multiple Sclerosis Journal

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS – YES

(2016) Jeremy Chataway   Multiple Sclerosis Journal

Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study

(2016) Marcus D’Souza et al.   Multiple Sclerosis Journal

Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

(2016) Patrick Vermersch et al.   Multiple Sclerosis Journal

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

(2016) Diego Cadavid et al.   Multiple Sclerosis Journal

Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes

(2016) Luis Ruano et al.   Multiple Sclerosis Journal

Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS – YES

(2016) Jeremy Chataway   Multiple Sclerosis Journal

Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study

(2016) Marcus D’Souza et al.   Multiple Sclerosis Journal

Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

(2016) Patrick Vermersch et al.   Multiple Sclerosis Journal

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

(2016) Diego Cadavid et al.   Multiple Sclerosis Journal

Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes

(2016) Luis Ruano et al.   Multiple Sclerosis Journal

Defining reliable disability outcomes in multiple sclerosis

(2015) Tomas Kalincik et al.   BRAIN

On the origin of Neurostatus

(2015) Ludwig Kappos et al.   Multiple Sclerosis and Related Disorders

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis

(2014) Sandra Meyer-Moock et al.   BMC Neurology

Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial

(2014) David M. Erlanger et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Composite end points to assess delay of disability progression by MS treatments

(2014) J Zhang et al.   Multiple Sclerosis Journal

The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis

(2014) Jeffrey A. Cohen et al.   JAMA Neurology

Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis

(2013) Yvonne C Learmonth et al.   BMC Neurology

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

(2013) John Zajicek et al.   LANCET NEUROLOGY

Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan

(2013) Richard A Rudick et al.   Multiple Sclerosis Journal

The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis

(2013) Yvonne C Learmonth et al.   Multiple Sclerosis Journal

Disability in multiple sclerosis: A reference for patients and clinicians

(2013) I. Kister et al.   NEUROLOGY

How People with Multiple Sclerosis Rate Their Quality of Life: An EQ-5D Survey via the UK MS Register

(2013) Kerina H. Jones et al.   PLoS One

Patient Reported Outcomes (PROs) in Clinical Trials: Is ‘In-Trial’ Guidance Lacking? A Systematic Review

(2013) Derek G. Kyte et al.   PLoS One

Accelerometry as a measure of walking behavior in multiple sclerosis

(2012) R. W. Motl et al.   ACTA NEUROLOGICA SCANDINAVICA

Brief International Cognitive Assessment for MS (BICAMS): international standards for validation

(2012) Ralph HB Benedict et al.   BMC Neurology

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

(2012) Jeffrey A Cohen et al.   LANCET NEUROLOGY

The effects of clinical interventions on health-related quality of life in multiple sclerosis: a meta-analysis

(2012) Ayse Kuspinar et al.   Multiple Sclerosis Journal

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

(2012) D Ontaneda et al.   Multiple Sclerosis Journal

Reliability and clinical significance of mobility and balance assessments in multiple sclerosis

(2012) Yvonne C. Learmonth et al.   INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Safety and Feasibility of Autologous Bone Marrow Cellular Therapy in Relapsing-Progressive Multiple Sclerosis

(2010) C M Rice et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Integration of Cognitive Impairment in the Expanded Disability Status Scale of 215 Patients with Multiple Sclerosis

(2010) Hélène Brissart et al.   EUROPEAN NEUROLOGY

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

(2010) SA Morrow et al.   Multiple Sclerosis Journal

Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study

(2010) Maria P Amato et al.   Multiple Sclerosis Journal

MRI and cognition in multiple sclerosis

(2010) M. Filippi et al.   NEUROLOGICAL SCIENCES

Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity

(2009) E M Mowry et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls

(2007) Myla D Goldman et al.   Multiple Sclerosis Journal